#Non-steroidal Anti-inflammatory Drugs Market Segmentation

[spermarket]

Non-steroidal Anti-inflammatory Drugs Market Trends, Share, Revenue, Outlook and Future Opportunities: SPER Market Research

Non-steroidal anti-inflammatory medications are often used to treat pain, inflammation, and fever. They are commonly used to relieve arthritis, muscle aches, headaches, menstrual cramps, and minor injuries such as sprains and strains. NSAIDs inhibit the formation of substances called prostaglandins in the body, which are responsible for pain and inflammation. 

These drugs, such as ibuprofen (Advil, Motrin) and naproxen (Aleve), are frequently available in over-the-counter and prescription strength formulations. NSAIDs are often taken orally, however some can be used topically as creams or gels to alleviate localized pain. 

According to SPER market research, ‘Global Non-steroidal Anti-inflammatory Drugs Market Size- By Disease Indication, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Non-steroidal Anti-inflammatory Drugs Market is predicted to reach 40.44 billion by 2034 with a CAGR of 5.92%. 

Drivers: 

The NSAIDs market is expanding rapidly because to the increasing prevalence of chronic pain and inflammatory disorders such as arthritis and migraines. This demand is being driven by an increasing senior population, which is more sensitive to these illnesses, as well as a growing preference for NSAIDs due to their lower side effect profile when compared to alternative pain medicines. Furthermore, the market is being bolstered by an increase in medicinal approvals, new product launches, and increased R&D activity. 

Request a Free Sample Report: https://www.sperresearch.com/report-store/non-steroidal-anti-inflammatory-drugs-market.aspx?sample=1

Restraints: 

The broad use of NSAIDs is limited by the possibility of major side effects such as cardiovascular events, gastrointestinal issues, renal failure, and hypersensitivity responses. Despite the relatively low individual risk for each patient, the cumulative usage of NSAIDs throughout populations increases the overall risk of adverse effects. This needs a rigorous review of individual patient risk factors before to prescribing NSAIDs, limiting the growth of the anti-inflammatory medications industry. Healthcare practitioners must weigh the therapeutic benefits of NSAIDs against the dangers they pose in order to ensure patient safety and regulatory compliance in clinical practice. 

North America dominated the global non-steroidal anti-inflammatory medicines industry, accounting for a sizable revenue share in 2024; the sector is predicted to develop significantly, affected by a number of major variables. A vast number of manufacturers and prominent companies' strategic endeavors are driving market growth. Some significant market players are Pfizer Inc, Bayer AG, GSK plc, Dr. Reddy’s Laboratories Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson Services, Merck & Co, Inc. and others.

For More Information, refer to below link: –  

Non-steroidal Anti-inflammatory Drugs Market Growth

Related Reports:  

Clinical Nutrition for Diabetes Care Market Growth, Size, Trends Analysis - By Product, By Stage, By Sales Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Cold Pain Therapy Market Growth, Size, Trends Analysis - By Product, By Application, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

enquiries@sperresearch.com 

+1–347–460–2899

[anujmrfr]

Avascular Necrosis Market Size, Growth Outlook 2035

Avascular Necrosis Market Size was valued at USD 0.53 Billion in 2023. The Avascular Necrosis market industry is projected to grow from USD 0.564 Billion in 2024 to USD 0.881 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period (2024 - 2032).

Executive Summary

The Avascular Necrosis (AVN) Market is expected to grow steadily, driven by rising awareness of the condition, advances in treatment options, and improving healthcare infrastructure globally. Avascular necrosis refers to the death of bone tissue due to a lack of blood supply, most commonly affecting the hip joint. The market's growth is propelled by advancements in surgical techniques, such as bone grafts and joint replacement surgeries, as well as increased government initiatives for better treatment access.

Market Overview

Avascular necrosis, also known as osteonecrosis, can lead to the collapse of bone structures, causing pain and requiring surgical intervention. Avascular Necrosis Market Size was valued at USD 0.53 Billion in 2023. The Avascular Necrosis market industry is projected to grow from USD 0.564 Billion in 2024 to USD 0.881 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period (2024 - 2032).

Market Drivers

Increased Awareness and Early Diagnosis: Advances in imaging techniques, such as MRI and CT scans, allow for earlier detection, enabling better management of AVN.

Improved Treatment Options: The availability of advanced treatments like core decompression and joint replacement surgery has improved the outlook for patients with AVN.

Rising Incidence of Risk Factors: Increased incidences of conditions like alcoholism, steroid use, and trauma—known risk factors for AVN—are driving the demand for better treatments.

Market Restraints

High Treatment Costs: The cost of joint replacement surgery and other advanced procedures remains a significant barrier, especially in low-income regions.

Limited Access to Healthcare: In certain regions, lack of access to specialized care and diagnostic tools hinders early detection and treatment of AVN.

Regional Analysis

North America: The North American market is driven by high healthcare spending, the presence of advanced surgical techniques, and a growing patient population suffering from AVN.

Europe: In Europe, countries such as Germany and France are witnessing steady market growth, supported by an aging population and increasing healthcare investments.

Asia-Pacific: The Asia-Pacific region shows immense potential for growth, especially in countries like Japan, China, and India, due to improving healthcare infrastructure and rising awareness.

Segmental Analysis

By Treatment Type:

Medication (Non-steroidal Anti-inflammatory Drugs, Bisphosphonates)

Core Decompression

Bone Grafting

Joint Replacement Surgery

Other Surgical Interventions

By End-User:

Hospitals

Orthopedic Clinics

Rehabilitation Centers

Key Market Players

Leading companies which deals in Avascular Necrosis are

Novartis AG

Pfizer Inc

Teva Pharmaceutical Industries Ltd

Mylan N.V

Zimmer Biomet

Merck & Co. Inc

Enzo Biochem Inc

Recent Developments

Advances in Minimally Invasive Techniques: The development of minimally invasive surgeries like core decompression is offering patients better outcomes with shorter recovery times.

Research in Stem Cell Therapy: Ongoing research into stem cell-based therapies for AVN could provide groundbreaking treatments in the near future.

For more information, please visit @marketresearchfuture

[metatechinsights]

Pet Arthritis Market Size, Share & Growth Forecast 2025-2035

Industry Outlook

The Pet Arthritis market accounted for USD 3.53 Billion in 2024 and is expected to reach USD 8.15 Billion by 2035, growing at a CAGR of around 7.9% between 2025 and 2035. The Pet Arthritis Market focuses on the diagnosis, treatment, and management of arthritis in pets, fundamentally dogs and cats. This sector incorporates a variety of products such as medications, dietary supplements, therapeutic devices, and alternative treatments outlined to lighten joint pain and improve mobility. With the expanding life span of pets and a developing awareness of animal wellbeing, this market is extending quickly. Key players are presenting innovative solutions, such as natural supplements and regenerative treatments, catering to the rising demand for effective and holistic treatment alternatives. The market moreover reflects the trend of pet humanization, where owners seek quality care for their aging pets. 

Report Scope:

2024

2035Market Size in 2024 & 203510.008.006.004.002.000.0020242035ParameterDetailsLargest MarketNorth AmericaFastest Growing MarketAsia PacificBase Year2024Market Size in 2024USD 3.53 BillionCAGR (2025-2035)7.9%Forecast Years2025-2035Historical Data2018-2024Market Size in 2035USD 8.15 BillionCountries CoveredU.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, Switzerland, Sweden, Finland, Netherlands, Poland, Russia, China, India, Australia, Japan, South Korea, Singapore, Indonesia, Malaysia, Philippines, Brazil, Argentina, GCC Countries, and South AfricaWhat We CoverMarket growth drivers, restraints, opportunities, Porter’s five forces analysis, PESTLE analysis, value chain analysis, regulatory landscape, pricing analysis by segments and region, company market share analysis, and over 10 companiesSegments CoveredProduct Type, Pet Type, Route of Administration, Distribution Channel and Region

To explore in-depth analysis in this report - Request Free Sample Report

Market Dynamics

Rising demand for natural and alternative arthritis treatments is driving market growth

The rising demand for natural and alternative arthritis medications is basically driving growth in the Pet Arthritis Market as pet owners dynamically look for holistic choices for directing their pets' wellbeing. Concerns around the side impacts of traditional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), have driven various owners to examine more normal cures. A overview conducted by the American Pet Products Association (APPA) indicates that 45% of pet owners prefer natural products when considering their pets' prosperity and wellness. This move towards characteristic arrangements isn't as it were driven by the need to avoid potential adverse effects but additionally reflects a developing awareness of the benefits of holistic care for improving the quality of life in maturing pets.

In addition, the market for natural supplements is encountering quick improvement, with a wide amplify of products focused on joint health and generally well-being getting to be progressively accessible. The National Animal Supplement Council (NASC) detailed that the pet supplement industry has created significantly over the past few years, reaching over $1.2 billion in 2022, with joint health products being a key segment. Also, a study published in the Journal of the American Veterinary Medical Association found that 60% of pet owners are willing to consider alternative treatments, such as herbal supplements and acupuncture, for arthritis management. This assembly of components underscores a critical move in customer behavior, driving the improvement of the Pet Arthritis Market towards more normal and alternative treatment options. 

High costs of arthritis treatments limit accessibility for many pet owners.

High costs associated with arthritis treatments pose a significant restraint on the Pet Arthritis Market, limiting availability for many pet owners. Advanced treatment choices, including surgical medications and long-term medicine regimens, can become restrictively costly. According to the American Pet Products Association (APPA), around 40% of pet owners report that cost is a major obstruction to getting to necessary veterinary care. This financial burden can lead to delayed treatment or the deserting of care inside and out, which negatively impacts the quality of life for pets enduring from arthritis.

Besides, pet insurance coverage for arthritis treatments is frequently lacking, assist exacerbating the issue. A study by the North American Pet Health Insurance Association (NAPHIA) shows that only about 30% of pets are insured, and numerous policies don't cover long-term or chronic conditions like arthritis. This need of coverage strengths pet owners to pay out-of-pocket, driving to intense choices about their pets' healthcare. As a result, the high costs of treatment not only confine get to to effective care but also highlight the require for more reasonable and available choices in the Pet Arthritis Market. 

Innovations in treatment modalities are introducing new, non-invasive options for managing pet arthritis.

Innovations in treatment modalities are significantly driving growth in the Pet Arthritis Market by introducing new, non-invasive options for managing arthritis in pets. Advances in veterinary medication have driven to the improvement of inventive treatments such as laser treatment, hydrotherapy, and regenerative medications like platelet-rich plasma (PRP) therapy and stem cell treatment. These non-invasive strategies not only reduce the distress related with traditional treatments but moreover advance faster recovery times and progressed generally health. According to a study published in the Journal of the American Veterinary Medical Association, about 70% of veterinarians report positive results in arthritis management when utilizing these progressed treatment options, indicating a move in how pet arthritis is approached.

Moreover, the developing acceptance and integration of innovation in veterinary care have improved the viability of these developments. For occurrence, veterinary telemedicine is gaining traction, permitting pet owners to consult with masters remotely and get to innovative medications without the require for obtrusive methods. A report by the American Veterinary Medical Association (AVMA) indicates that telehealth utilize in veterinary practice has expanded by over 30% in later years. This mechanical advancement not only makes care more accessible but also allows for personalized treatment plans tailored to individual pets' needs. The rise of imaginative, non-invasive treatment modalities is reshaping the Pet Arthritis Market, offering pet owners successful arrangements that improve their pets' quality of life whereas reducing the risks related with traditional treatments.

Industry Experts Opinion

“I was excited to participate as a clinical investigator in the Zenrelia field study because it is clear we need more treatment options for itchy dogs,"

-  Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals

 “We’ve seen how this has really taken off in the human health space in the past few decades, and we have just begun to see the positive impact that biological therapies can have in the animal health space. We definitely see a bright future for this.”

- Dirk E. Polzer, the Chief Medical Officer (CMO) at Elanco Animal Health

Segment Analysis

Based on product type, the Pet Arthritis Market is divided into Medications, Assistive Devices and Alternative Therapies, Nutritional Supplements, and Others. The Medications segment contains NSAIDs and corticosteroids, Then Assistive Devices feature joint braces and mobility aids. The Alternative Therapies having treatments like acupuncture & laser therapy, and Nutritional Supplements encompass products with glucosamine and omega-3 fatty acids. The Others category covers additional products and services for managing pet arthritis.

You can also buy individual sections of this report.

Would you like to review the price list for each section?

Request Sectional Data

[healthcarefuture]

Analyzing the Competitive Landscape of the Eczema Treatment Market

Eczema, also known as atopic dermatitis, is a common, chronic skin condition that causes inflammation, redness, and itching. People with eczema often experience flare-ups, which can significantly impact their quality of life. As the prevalence of eczema increases worldwide, there is a growing demand for effective treatments. Eczema Therapeutics includes a range of options such as topical steroids, non-steroidal anti-inflammatory creams, biologics, and lifestyle modifications. The Eczema Therapeutics market has shown substantial growth, fueled by increasing awareness, technological advancements in treatments, and a rising number of clinical trials focused on finding more effective therapies.

In 2022, the market size for eczema treatments was projected to be 9.44 billion USD. By 2032, the eczema therapeutics market is projected to have grown from 9.93 billion USD in 2023 to 15.7 billion USD. During the 2024–2032 forecast period, the Eczema Therapeutics Market is anticipated to increase at a CAGR of around 5.22%.

Eczema Therapeutics Size and Share

The Eczema Therapeutics market has expanded significantly, driven by a growing patient base and ongoing research efforts. In recent years, the market size for Eczema Therapeutics has witnessed a compound annual growth rate (CAGR) that reflects both increased demand and innovation. Eczema Therapeutics share is primarily distributed across major pharmaceutical companies investing in the development of biologic drugs, topical treatments, and other advanced options. With significant progress in drug approvals and new players entering the market, the Eczema Therapeutics share is expected to diversify further, creating opportunities for both existing and emerging companies.

Eczema Therapeutics Analysis

In-depth analysis of the Eczema Therapeutics market reveals that treatment options are becoming more personalized and effective. Conventional topical treatments remain widely used due to their accessibility and cost-effectiveness. However, biologics and other advanced therapeutics are gaining popularity for their targeted mechanisms, which can reduce side effects and improve patient outcomes. Eczema Therapeutics analysis highlights the growing preference for therapies with a strong safety profile and long-lasting efficacy. Additionally, the analysis shows that unmet needs for pediatric eczema treatments are driving research and development (R&D) efforts, as younger patients represent a large portion of the affected population.

Eczema Therapeutics Trends

Emerging Eczema Therapeutics trends include the rise of biologic drugs, which target specific pathways involved in the immune response, providing relief to patients who do not respond to traditional treatments. Another key trend is the development of non-steroidal topical options, which cater to patients seeking alternatives to steroids due to concerns about side effects. Digital health tools, such as mobile apps and wearables, are also being integrated to support remote monitoring and management of eczema symptoms, reflecting an increased emphasis on personalized care. Eczema Therapeutics trends additionally show a shift toward over-the-counter options and holistic approaches, including dietary adjustments and lifestyle changes, which are gaining traction among patients looking for natural and complementary therapies.

Reasons to Buy Eczema Therapeutics Reports

Comprehensive Market Insights: The report provides an in-depth look at the Eczema Therapeutics market, covering its size, share, trends, and analysis. This is valuable for stakeholders looking to make informed investment and business decisions.

Detailed Competitive Landscape: With detailed information on major players and their strategies, the report helps stakeholders understand competitive positioning in the Eczema Therapeutics market.

Identification of Growth Opportunities: Buyers gain insight into emerging segments and trends in Eczema Therapeutics, enabling them to leverage new opportunities for growth and innovation.

R&D and Innovation Focus: The report sheds light on recent research, development activities, and technological advances, crucial for companies seeking to stay ahead in the Eczema Therapeutics market.

Market Forecast and Projections: Detailed forecasts help stakeholders plan for future developments, ensuring they stay updated with upcoming market changes and potential demand fluctuations.

Recent Developments in Eczema Therapeutics

Recent developments in Eczema Therapeutics include FDA approval of novel biologic drugs that offer targeted relief for patients with moderate to severe eczema. These biologics represent a breakthrough for patients who have not found success with conventional treatments. Another significant advancement is the increased focus on gene therapy, with several companies conducting clinical trials exploring genetic approaches to managing eczema. Additionally, new non-steroidal topical treatments have entered the market, offering alternatives for those seeking to minimize steroid exposure. Digital health integration, with mobile applications for symptom tracking, is also on the rise, supporting both patients and healthcare providers in better managing eczema. Finally, several pharmaceutical companies have announced collaborations aimed at developing next-generation eczema treatments, signaling ongoing investment in innovation within the Eczema Therapeutics market.

Related reports:

medical kiosk market

molecular quality control market

next generation solar cell market

non invasive aesthetic treatment market

Top of Form

Bottom of Form

[healthcare-skyquest]

Pain Management Drugs Market: Addressing Global Health Needs

The Pain Management Drugs Market plays a crucial role in improving quality of life by providing relief for various acute and chronic pain conditions. As demand for effective pain relief rises, the market is witnessing substantial growth. This article explores the latest trends, market segmentation, key growth drivers, and leading companies in the pain management drugs sector, offering key insights for decision-makers.

Market Overview

According to SkyQuest’s Pain Management Drugs Market report, the market is projected to grow at a CAGR of XX%. Factors such as the increasing prevalence of chronic diseases, advancements in drug formulations, and growing awareness of pain management solutions are driving market growth.

Request Your Free Sample: - https://www.skyquestt.com/sample-request/pain-management-drugs-market

Market Segmentation

By Drug Class:

Opioids: Widely prescribed for severe pain but associated with risks of addiction and side effects.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Commonly used for mild to moderate pain, especially in conditions like arthritis.

Anticonvulsants: Effective in managing nerve pain and neuropathy.

Antidepressants: Used in cases of chronic pain, particularly when linked to depression or anxiety.

Others: Includes topical treatments and alternative pain relief solutions.

By Pain Type:

Chronic Pain: Long-term pain associated with conditions like arthritis, cancer, and back pain.

Acute Pain: Short-term pain caused by injury, surgery, or trauma.

Neuropathic Pain: Arising from nerve damage, often seen in diabetes and multiple sclerosis patients.

By Distribution Channel:

Hospital Pharmacies: Primary distribution point for prescription pain management drugs.

Retail Pharmacies: Widely used for over-the-counter and prescription pain relief medications.

Online Pharmacies: Gaining popularity for the convenience and ease of access they provide to patients.

Key Growth Drivers

Increasing Prevalence of Chronic Conditions: Growing numbers of patients suffering from arthritis, cancer, and neuropathy drive demand for pain relief solutions.

Advancements in Drug Formulations: New drug formulations with fewer side effects and longer-lasting effects are fueling market growth.

Rising Awareness About Pain Management: Increasing patient awareness about the importance of pain management and the availability of various treatment options.

Aging Population: The global aging population is more susceptible to chronic pain, leading to increased demand for pain management drugs.

Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/pain-management-drugs-market

Leading Companies in the Market

SkyQuest’s report highlights key players leading the Pain Management Drugs Market, including:

Pfizer Inc.

Johnson & Johnson

Eli Lilly and Company

GlaxoSmithKline plc

AbbVie Inc.

AstraZeneca

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

Endo Pharmaceuticals

Read More at: - https://www.skyquestt.com/report/pain-management-drugs-market

Challenges and Opportunities

Challenges in the market include the opioid crisis, with governments and regulatory bodies imposing stricter controls on opioid use. However, these challenges open opportunities for the development of non-addictive pain relief alternatives and innovative formulations.

Future Outlook

The Pain Management Drugs Market is expected to experience steady growth, with an increasing focus on non-opioid alternatives and personalized pain management solutions. Companies that invest in research and development of safer, more effective drugs will be at the forefront of this evolving market.

The Pain Management Drugs Market is critical to improving the quality of life for millions of people worldwide. As the market continues to evolve, healthcare decision-makers must stay informed of emerging trends and innovations. For a more in-depth analysis, refer to SkyQuest’s comprehensive Pain Management Drugs Market report.

[poonamcmi]

Over The Counter Pain Medication market will grow at highest pace owing to rising geriatric population

The over the counter pain medication market consists of non-prescription drugs used to relieve pain such as headaches, muscle pains, backaches, toothaches, colds, menstrual cramps and arthritis. These drugs provide temporary relief from pain and include analgesics like paracetamol and non-steroidal anti-inflammatory drugs such as ibuprofen and aspirin. Non-prescription pain medications are widely available as tablets, capsules and liquids in retail pharmacies and online stores, providing convenience to consumers. With growing aging population suffering from arthritis and other joint pains, the demand for these medications is increasing rapidly.

The Global Over The Counter Pain Medication Market is estimated to be valued at US$ 27.12 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Over The Counter Pain Medication market include Johnson & Johnson, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Reckitt Benckiser Group plc, Novartis AG, Perrigo Company plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited. The dominance of these key players is attributed to their diverse product portfolio and strong global distribution network.

Over The Counter Pain Medication Market Demand rapidly owing to increasing incidences of headache, joint pains and menstrual problems across major countries. Self-medication has become popular as consumers frequently purchase these drugs for quick relief from minor pains without doctor's prescription.

Technological advancements are leading to development of innovative drug delivery systems for over the counter pain medications such as fast-dissolving oral thin films and gels providing pain relief more quickly. Development of combination drugs offering relief from multiple symptoms with a single drug is another key trend observed in this market. Market Trends Sustained release formulations are gaining popularity in the over the counter pain medication market. These ensure drugs remain effective for longer duration, releasing medicine slowly into the body. For example, Advil has introduced extended release gels providing all-day relief from pain.

Combination drugs offering relief from pain as well as symptoms like cold, cough and fever are witnessing strong demand. Consumers prefer single drugs treating multiple conditions. Manufacturers are developing combination pills accordingly to increase sales.

Market Opportunities The rising geriatric population suffering from arthritis and joint pains worldwide presents significant growth opportunities. Around 100 million US adults suffer from arthritis currently and the number is projected to rise to 130 million by 2060.

Online pharmacies are emerging as an important sales channel for over the counter pain medications. Expanding e-commerce and increasing preference of consumers to shop online from the convenience of their homes will drive future revenues in this distribution segment.

Impact of COVID-19 on Over The Counter Pain Medication Market Size And Trends  The COVID-19 pandemic has immensely impacted the growth of the over the counter pain medication market globally. During the initial phase of the pandemic, there was a sharp surge in demand for pain relieving drugs like paracetamol, ibuprofen etc. as people stocked up medicines fearing potential shortages. This led to a significant spike in sales revenues for OTC pain medication manufacturers in 2020. However, as the pandemic prolonged, lockdowns imposed worldwide disrupted manufacturing and supply chain operations. Strict movement restrictions made it difficult for companies to transport raw materials and finished drugs. The declining disposable incomes and job losses during the economic downturn also reduced people's spending power which hindered the market growth post-2020.

To overcome resource constraints, companies focused on streamlining production and prioritizing essential medicines. They established alternative sourcing routes and enhanced inventory levels. Digitization of processes helped maintain business continuity. As restrictions eased in 2021-22, market saw a steady recovery backed by mass vaccination drives. Demand revived in retail channels and e-commerce platforms. However, hovering price pressures due to high production costs remain a key challenge. In the coming years, companies need to optimize costs, expand into virtual care solutions and tap opportunities in pain relief for Covid-19 associated symptoms to sustain growth in the post pandemic environment. Geographical Regions with Highest Over The Counter Pain Medication Market Value ​North America has been the largest regional market for over the counter pain medication, accounting for around 40% of global value due to high healthcare spending and self-medication trend. Within North America, the US commands the major share owing to large population size and presence of major manufacturers. Europe holds the second position while Asia Pacific is fastest growing region supported by expanding medical industries, rising health awareness and large patient pool in China and India. Fastest Growing Region in Over The Counter Pain Medication Market Asia Pacific region is poised to witness the fastest growth in the over the counter pain medication market during the forecast period. Factors such as rising middle class disposable incomes, increased spending on healthcare, growing geriatric population susceptible to joint disorders and innovations by local pharmaceutical giants are driving the market growth in Asia Pacific countries. Additionally, self-medication has become more prominent with easier access to OTC drugs via e-retailers and convenience stores. China, India, Japan, South Korea, Indonesia and other Southeast Asian countries offer immense untapped opportunities for OTC painkiller brands seeking to expand in Asia. Get More Insights On, Over The Counter Pain Medication Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[twbcx]

Vet2Trade Business Report: Comparison of the key trends and players in India and the US – by Rakesh Shukla, vet2trade.market

Executive Summary

The veterinary market is segmented into several primary categories, including companion animals, livestock, and various services like diagnostics, therapeutics, and pet food. This report details these segments and examines the differences in the Indian and US markets in terms of segmentation, relative size, growth, and trends. Key trends such as technological advancements, drug developments, and healthcare improvements are highlighted. This report also provides a granular analysis of urban vs. rural areas within each country and identifies major players in the industry, especially those operating in both India and the US.

Primary Segments in the Veterinary Market

1. Companion Animals

●      Diagnostics: Includes diagnostic imaging, blood tests, and genetic testing.

●      Therapeutics: Encompasses medications and treatments for diseases and conditions.

●      Pet Food: Nutritional products tailored for various breeds and health conditions.

●      Services: Routine check-ups, vaccinations, and emergency care.

2. Livestock

●      Diagnostics: Disease testing and monitoring.

●      Therapeutics: Veterinary drugs and vaccines for disease prevention and treatment.

●      Nutrition: Feed supplements and nutritional products to enhance productivity and health.

●      Services: Breeding, health monitoring, and surgical procedures.

Comparison of Veterinary Markets: India vs. US

Market Size and Growth

●      US Market:

●      The US veterinary market is one of the largest globally, with a market size of approximately $45 billion in 2023, growing at a CAGR of 5% over the past five years.

●      The companion animal segment dominates, driven by high pet ownership rates and significant spending on pet healthcare and wellness.

●      Indian Market:

●      The Indian veterinary market is smaller but rapidly growing, with a market size of about $1.4 billion in 2023, and a higher CAGR of 8% over the past five years.

●      The livestock segment is more prominent due to the agrarian economy and reliance on livestock for income.

Granular Analysis

●      Urban vs. Rural:

●      US: Urban areas show higher expenditure on companion animals with a focus on advanced diagnostics and therapeutics. Rural areas focus more on livestock services.

●      India: Urban regions are seeing increasing pet ownership and related services, but rural areas still largely depend on livestock veterinary services for economic reasons.

Trends

1. Technological Advancements:

●      US:

●      Telemedicine: Companies like Fuzzy Pet Health and PetDesk are providing telehealth services, enabling pet owners to consult veterinarians remotely, enhancing access to veterinary care.

●      AI-driven Diagnostics: Firms like SignalPET use artificial intelligence to interpret radiographs, improving diagnostic accuracy and speed.

●      Wearable Health Monitoring Devices: Products like the Whistle GPS Pet Tracker and FitBark monitor pet activity and health metrics, providing real-time data to veterinarians and pet owners.

●      India:

●      Telemedicine: Platforms such as Practo and VetnCare offer teleconsultation services, particularly beneficial in remote areas where veterinary facilities are scarce.

●      Mobile Apps: PetKonnect and Woofwoofnow provide veterinary consultation, health tracking, and service bookings, making veterinary care more accessible to urban pet owners.

2. Drug Developments:

●      US:

●      Biologics: Zoetis’ Cytopoint, a monoclonal antibody therapy, provides targeted treatment for canine atopic dermatitis, representing a shift towards precision medicine in veterinary care.

●      Novel Therapies: Elanco’s Galliprant, a non-steroidal anti-inflammatory drug (NSAID), offers an innovative approach to managing canine osteoarthritis with fewer side effects compared to traditional NSAIDs.

●      India:

●      Affordable Generics: Companies like Hester Biosciences focus on producing cost-effective generic vaccines and medications for livestock, such as Hester’s ND+IB vaccine for poultry.

●      Veterinary Vaccines: Indian Immunologicals Limited (IIL) has developed Raksha Ovac, a vaccine for ovine footrot, addressing a significant health issue in sheep farming.

3. Healthcare Improvements:

●      US:

●      Specialized Veterinary Practices: The rise of specialty clinics like VCA Animal Hospitals and BluePearl Veterinary Partners, which offer advanced services such as oncology, cardiology, and neurology, reflects a trend towards specialized and comprehensive pet healthcare.

●      Wellness Programs: Companies like Banfield Pet Hospital offer Optimum Wellness Plans, which include preventive care, vaccinations, and routine health checks, promoting proactive health management for pets.

●      India:

●      Advanced Treatments: Veterinary hospitals like Cessna Lifeline in Bangalore provide state-of-the-art treatments including endoscopy, orthopedic surgeries, and critical care, bringing advanced veterinary services to urban pet owners.

●      Preventive Care: NGOs and veterinary organizations are increasingly focusing on preventive care programs, such as regular vaccination drives and health camps for livestock in rural areas, improving overall animal health and productivity.

Key Players in the Veterinary Market

US

Zoetis Inc.

●      Market Share: Zoetis is the largest global player in animal health with a significant market share.

●      Technical Differentiators: Leading in research and development with innovative vaccines, parasiticides, and diagnostic products.

●      Key Market Segments: Companion animals and livestock.

●      Product Brands:

●      Companion Animals: Simparica Trio (parasiticide), Cytopoint (atopic dermatitis treatment).

●      Livestock: Draxxin (antibiotic), Excede (antibiotic).

2. IDEXX Laboratories

●      Market Share: A major player in veterinary diagnostics.

●      Technical Differentiators: Cutting-edge diagnostic technology and software solutions.

●      Key Market Segments: Companion animals.

●      Product Brands:

●      Diagnostics: Catalyst One (chemistry analyzer), SNAP tests (rapid diagnostic tests).

3. Boehringer Ingelheim

●      Market Share: Significant global presence in animal health.

●      Technical Differentiators: Strong focus on vaccines and therapeutics, innovative R&D.

●      Key Market Segments: Companion animals, livestock, poultry.

●      Product Brands:

●      Companion Animals: NexGard (parasiticide), Heartgard (heartworm prevention).

●      Livestock: Ingelvac (swine vaccines), Bovikalc (cattle supplement).

India

1. Hester Biosciences

●      Market Share: Leading in the poultry vaccine market in India.

●      Technical Differentiators: Extensive vaccine production capabilities, focus on affordability.

●      Key Market Segments: Poultry, livestock.

●      Product Brands:

●      Poultry: Hester ND+IB (Newcastle and Infectious Bronchitis vaccine), Hester Coryza (fowl coryza vaccine).

2. Venkys India

●      Market Share: Major player in the poultry segment.

●      Technical Differentiators: Comprehensive product portfolio for poultry health and nutrition.

●      Key Market Segments: Poultry.

●      Product Brands:

●      Nutrition: Venky’s India feed supplements.

●      Health Products: Vetcom (medications for poultry).

Companies Operating in Both Markets

1. Boehringer Ingelheim

●      Market Share: Substantial presence in both India and the US.

●      Technical Differentiators: Advanced R&D, extensive portfolio in vaccines and therapeutics.

●      Key Market Segments: Companion animals, livestock, poultry.

●      Product Brands: (See above)

2. Elanco Animal Health

●      Market Share: Strong market position globally, including India and the US.

●      Technical Differentiators: Focus on innovation, broad portfolio across species.

●      Key Market Segments: Companion animals, livestock.

●      Product Brands:

●      Companion Animals: Trifexis (parasiticide), Galliprant (arthritis treatment).

●      Livestock: Rumensin (feed additive), Imrestor (immunostimulant).

3. Merck Animal Health

●      Market Share: Leading player in animal health with operations in both countries.

●      Technical Differentiators: Comprehensive solutions, advanced biologics.

●      Key Market Segments: Companion animals, livestock, poultry.

●      Product Brands:

●      Companion Animals: Bravecto (flea and tick treatment), Nobivac (vaccines).

●      Livestock: Zilmax (beef cattle feed additive), Safe-Guard (anthelmintic).

Conclusion

The veterinary markets in India and the US show significant differences in size, growth, and focus. The US market is more developed with a strong emphasis on companion animals, advanced diagnostics, and therapeutic services. In contrast, the Indian market, while smaller, is growing rapidly with a primary focus on livestock health. Both markets are experiencing trends driven by technological advancements and healthcare improvements, though the pace and focus of these trends vary. Key players like Boehringer Ingelheim, Elanco, and Merck are instrumental in shaping the veterinary landscape in both countries.

About Vet2Trade™

Vet2Trade™ is part of Rakesh Shukla-led VOSD Corporation. Vet2Trade™ is India’s largest B2B platform for the veterinary industry, bringing together Medical Equipment and Instruments, Medical Supplies and Accessories, Pharmaceuticals and Medications, Pet Services, and Pet Care in a single marketplace. Vet2Trade™ brings together various players in the veterinary industry and operates as a reliable, quality-driven platform ensuring convenience and competitive pricing for all its users.

VOSD Corporation™ is a holding company that creates and delivers India’s most beloved pet brands & businesses to pet parents across veterinary care, pet transport, lifestyle, vet pharma, and pet food. These include Vet2Trade™, VOSD AI™, VOSD Advance Vet Care™, VOSD Brands™ and VOSD-on-Wheels™. Together these companies fund the VOSD Trust™ — the world’s largest dog rescue.

About Rakesh Shukla

Rakesh Shukla is the foremost expert on dogs in India & the founder of the VOSD Trust™ — the world’s largest dog rescue. Rakesh has spent 30 years creating several multimillion-dollar world-class software products & businesses. Rakesh manages a portfolio of successful startups –  in IT, PetTech, and RetailTech including VOSD™ Vet & Pet Corporation, TWBcx™, The Better Company™ & inStore™ Retail. The VOSD Trust™ is the sole financial survivor of Rakesh Shukla and all his investments and companies.

[spookysaladchaos]

Global Top 10 Companies Accounted for 73% of total Celecoxib API market (QYResearch, 2021)

Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility.

The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.

According to the new market research report “Global Celecoxib API Market Report 2023-2029”, published by QYResearch, the global Celecoxib API market size is projected to reach USD 0.08 billion by 2029, at a CAGR of 4.9% during the forecast period.

Figure.   Global Celecoxib API Market Size (US$ Million), 2018-2029

Figure.   Global Celecoxib API Top 10 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated)

The global key manufacturers of Celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Chiatai Qingjiang, Jiangsu Hengrui Medicine, Teva Pharmaceuticals, Viatris(Mylan), Aurobindo Pharma, Hisun Pharmaceutical Nantong, Punjab Chemicals, etc.

In 2022, the global top five players had a share approximately 73.0% in terms of revenue.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

For more information, please contact the following e-mail address:

Email: global@qyresearch.com

Website: https://www.qyresearch.com

[industryforecastnews]

U.S. Veterinary Orthopedic Medicine Market Size, Share & Growth Analysis Report, 2030

U.S. Veterinary Orthopedic Medicine Market Growth & Trends

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.    

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

U.S. Veterinary Orthopedic Medicine Market Report Highlights

Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period

Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade

Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period

Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade

On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

U.S. Veterinary Orthopedic Medicine Market Segmentation

Grand View Research has segmented the U.S. veterinary orthopedic medicine market based on product, animal type, application, route of administration, and end-use:

U.S. Veterinary Orthopedic Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)

Biologics

Stem Cells

Platelet-Rich Plasma (PRP)

Other Biologics

Viscosupplements

Pharmaceuticals

Steroids

NSAIDS

Others

U.S. Veterinary Orthopedic Medicine Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

Dogs

Small Breeds

Medium Breeds

Large Breeds

Horses

U.S. Veterinary Orthopedic Medicine Application Outlook (Revenue, USD Million; 2018 - 2030)

Osteoarthritis

Degenerative Joint Disease

Others

U.S. Veterinary Orthopedic Medicine Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Injectable

Intra-Muscular

Intra-Articular

Others

Oral

Others

U.S. Veterinary Orthopedic Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)

Veterinary Hospitals & Clinics

At-home

Others

List of Key Players in the U.S. Veterinary Orthopedic Medicine Market

Zoetis Services LLC

Ardent Animal Health, LLC

Enso Discoveries

VetStem, Inc.

Contura Vet

PetVivo Holdings, Inc.

T-Cyte Therepeutics

Boehringer Ingelheim International GmbH

Arthrex, Inc.

MEDREGO LLC

Nucleus ProVets

Daiichi Sankyo Company, Limited 

Bimeda U.S.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

[bhushans]

Global Over-The-Counter Pain Medication Market : A Deep Dive into Key Drivers and Trends

The global over-the-counter pain medication market is expected to grow rapidly, reaching a valuation of US$ 35,090.10 million by 2034. This increased trend is anticipated to be accelerated by an increase in the number of seniors and a growing consumer demand for better pain treatment choices.

Many consumers are turning to generic drugs in an effort to reduce their overall spending on over-the-counter (OTC) or non-prescription painkillers. To ensure the effectiveness and safety of over-the-counter medications, a number of regulatory bodies, including the US Food and Drug Administration (FDA), have established stringent criteria and labeling requirements.

Preview Next-Level Insights Sample : https://www.futuremarketinsights.com/reports/sample/rep-gb-8947

According to the report, acetaminophens are among the most often bought over-the-counter pain relievers, accounting for 45% of the market for these medications. According to the FMI report, demand for acetaminophen will stay strong in the future years due to its reputation as a safer pain reliever than other medications.

A recent study on the abuse of over-the-counter combination medications containing acetaminophen was released by the American trade body Consumer Healthcare medications body (CHPA). According to the study, exposures related to therapeutic abuse of over-the-counter combo medications including acetaminophen decreased by 28%.

Competitive Analysis:

Crucial suppliers of over-the-counter painkillers dominate much of the competitive environment in the market, stimulating innovation and changing the dynamics of the industry. Prominent manufacturers of over-the-counter pain relievers include Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., and GlaxoSmithKline plc.

To remain at the top of their respective marketplaces, take advantage of their diverse portfolios and worldwide connections. Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. are all significant players in this competitive over-the-counter pain medication industry, and each brings unique strategies and strengths to the fore.

These suppliers of over-the-counter painkillers employ a range of tactics, such as forceful advertising campaigns, business partnerships, and unique product offerings, to differentiate themselves from rivals and increase their market share. Constant efforts are made to enhance the convenience, safety, and efficacy of products in order to satisfy the diverse needs and preferences of consumers.

Distribution networks, brand recognition, and regulatory compliance are important variables influencing the strength of the over-the-counter painkiller business. Businesses devote a large amount of money on R&D, quality assurance, and customer service in order to maintain a competitive advantage and encourage sustainable growth.

Our Methodology Overview: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-8947

Pivotal Over-the-Counter (OTC) Pain Medication Vendors:

Pfizer Inc.

Johnson & Johnson Services Inc.

Bayer AG

Sanofi S.A.

GlaxoSmithKline plc.

Bristo-Meyers Squibb and Company

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Merck & Co.

Cardinal Health Inc.

Key Segments:

By Drug Class:

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Local Anaesthetics

Acetaminophen

By Route of Administration:

Oral

Topical

Others

By Dosage Form:

Tablets

Capsules

Creams

Gels

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores

Retail Stores

E-commerce

Others

By Region:

North America

Latin America

Europe

East Asia

South Asia and Pacific

Middle East and Africa (MEA)

[healthcareanna]

Autoimmune Disease Treatment Market Report Insights, Global Strategies & Growth Factors

Autoimmune Disease Treatment Market Overview

Market Research Future (MRFR)’s latest assessment reveals that the global autoimmune disease treatment market share is expected to thrive at Steady CAGR during the forecast period. The market signifies massive unmet needs for diagnosis. It is projected to favor the expansion of the global market by bringing advanced, precise and effective drugs and treatments.

Definite causes for the development of autoimmune diseases have not been identified. Thus, the emphasis is on the early diagnosis of the disease. Increasing awareness coupled with large-scale prevalence is likely to aid the proliferation of the Autoimmune Disease Treatment Market Overview in the foreseeable future.

Expenditures for the treatment of these diseases are on the rise and is poised to exhibit a similar trend in the forthcoming years. As per the National Institutes of Health (NIH), the U.S., the healthcare expenditure for autoimmune diseases has reached half of that of the cancer expenditure. Furthermore, the introduction of favorable policies for insurance reimbursements are anticipated to augment the market over the next couple of years. However, factors such as side effects, counterfeit drugs, and expensiveness of the treatment are forecasted to check the expansion of the autoimmune disease treatment market across the review period.

Competitive Dashboard:

Autoimmune Disease Treatment MarketPlayers are Abbott Laboratories, Genentech Inc., Bayer Schering Pharma AG, Amgen Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bio-Rad, Elan Corporation Plc, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Eli Lilly and Company, Johnson & Johnson Inc., Siemens, Squibb Company, Merck & Co. Inc., and Thermo Fisher Scientific.

Market Segmentation

By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.

By diagnosis, the autoimmune disease treatment market outlook has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

By therapeutic products, the market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis

The autoimmune disease treatment market report spans across Asia Pacific, Americas, Europe, and the Middle East & Africa. Americas signifies a huge potential for growth owing to increasing patient population. In addition, the increase witnessed in the expenditures associated with medical facilities is prognosticated to favor the expansion of the market over the next couple of years. The region has been estimated to gain control over the largest share of market in the forthcoming years.

The government of Europe has extended firm support in favor of research & development in the healthcare sector. This, in turn, is likely to pave the way for the growth of the in the region. It is expected to place the region on the second spot globally over 2023.

Asia Pacific has unleashed immense opportunities in the market through rapid developments witnessed in the healthcare sector. The population has also created a positive influence on the growth of the market by increasing its healthcare expenditures.

Related reports-

Heart Transplant Market Research Report - Global Forecast till 2030

Bladder Cancer Market Research Report - Forecast to 2030

CBD Hemp Oil Market Research Report – Forecast to 2030

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[rohans18]

Autonomic Dysreflexia Treatment Market Size, Reports, Demands, Share - Forecast 2028

Global Autonomic Dysreflexia Treatment Market, By Injury Type (Complete Spinal Cord Injury, Incomplete Spinal Cord Injury), Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAID’S), Anti-Depressants, Anticonvulsants, Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

In the consistent Autonomic Dysreflexia Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Autonomic Dysreflexia Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Autonomic Dysreflexia Treatment market report brings precise and exact market research information that drives business into the right direction.

Key Players

The major players covered in the Autonomic Dysreflexia Treatment market report are BioHorizons IPH, Inc., Floss Locations, Dr. Fresh LLC, Colgate-Palmolive Company, GlaxoSmithKline plc, 3M Company, Ultradent Products Inc., Bausch Health Companies Inc., Dentsply Sirona, Medtronic PLC, Zimmer Biomet Inc., Sunstar Suisse S.A. and PatientPop.Inc among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-autonomic-dysreflexia-treatment-market

The research studies entailed in the winning Autonomic Dysreflexia Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Autonomic Dysreflexia Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[delvenservices]

Osteoarthritis Treatment Market Overview & Forecast: 2028

Osteoarthritis Treatment Market is segmented by Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Hyaluronic acid Injection, and Other Drugs), Anatomy (Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, and OtherAnatomies), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

The Osteoarthritis Treatment Market is expected to witness a CAGR of 6.76% over the forecast period, 2021-2028.

Osteoarthritis, also known as degenerative arthritis, is the most commonly occurring chronic condition that affects the joints. This leads to severe joint pain and stiffness of the affected body parts. Osteoarthritis can be treated by several treatments, which include exercise for reducing joint pain, and pain medications.

The rising geriatric population, increasing incidence of osteoarthritis, and rising demand for minimally invasive surgical procedures are some of the factors that have supported long-term expansion for Osteoarthritis Therapeutics Market.

The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of infection, there is a possible reduction in the immune response for up to a few weeks following the procedure.

Request Sample Pages of Report: https://www.delvens.com/get-free-sample/osteoarthritis-therapeutics-market-trends-forecast-till-2028

Regional Analysis

The North American market is expected to grow, owing to the increasing lifestyle changes, an increasing number of obesity cases, and an extensive rise in the geriatric population in North America. As a result, the adoption of treatment and drugs is also increasing in the region. The availability of better treatment options, high awareness among people, government reimbursement policies, and the willingness to take up treatment is expected to add up to the growth of the osteoarthritis treatment market in the region.

Key Players

Sanofi SA

Pfizer Inc.

GlaxoSmithKline plc

Zimmer Biomet

Abbott Laboratories

Bayer AG

Anika Therapeutics

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/osteoarthritis-therapeutics-market-trends-forecast-till-2028

Recent Developments

In December 2020, Moebius Medical received the US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application to initiate a global multi-center Phase IIb clinical trial of MM-II, which is a novel candidate for the treatment of pain due to knee osteoarthritis (OA).

In February 2020, Anika Therapeutics Inc. acquired Arthosurface, which led to the expansion of the joint preservation and restoration product portfolio.

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Osteoarthritis Therapeutics Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Purchase the Report: https://www.delvens.com/checkout/osteoarthritis-therapeutics-market-trends-forecast-till-2028

Report Scope

Osteoarthritis Therapeutics Market is segmented into drugs, anatomy and region.

On the basis of Drugs

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Corticosteroids

Hyaluronic Acid Injection                     

On the basis of Anatomy

Ankle Osteoarthritis

Hip Osteoarthritis

Knee Osteoarthritis

Shoulder Osteoarthritis

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

Read More:

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

[the-rachana]

Kyphoscoliosis Therapeutics Market to hit US$ 4.49 by 2031: Growth Plus Reports

Newark, New Castle, USA - Kyphoscoliosis Therapeutics Market Analysis 2023 | Business Opportunities, Pricing Strategy, Forthcoming opportunities planning, Market-specific challenges, Globally Market Key Facts are coverd in this report by Growth Plus Reports | 100+ Report Pages

Kyphoscoliosis Therapeutics Market 2023 with 100+ Pages Report and enhance with extents shares into sub-counties are covered in this market. Kyphoscoliosis Therapeutics Market conditions can be influenced by a wide range of factors, including economic policies, geopolitical events, and technological developments.

Browse Market Size, charts, tables and figures extent in-depth TOC with 100+ Report Pages on Kyphoscoliosis Therapeutics Market, Business Outlook, Top Companies, Key Regions, Product Demand, Market Size and Growth.

Get a Sample PDF of Report at: https://www.growthplusreports.com/inquiry/request-sample/kyphoscoliosis-therapeutics-market/8751

SEGMENTATION

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Muscle Relaxants

Others

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY TYPE

Postural Kyphosis

Scheuermann's Kyphosis

Congenital Kyphosis

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Kyphoscoliosis Therapeutics market focuses on analyzing the current competitive situation in the Kyphoscoliosis Therapeutics market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, includes the highlighted analysis-Strategies for Company to Deal with the Impact of COVID-19, It may also be helpful to consult with a financial who can provide direction based on your specific financial situation and goals.

Top Key Players of the Market:

Amneal Pharmaceuticals LLC

Johnson and Johnson

Perrigo Company plc

Teva Pharmaceutical Industries Ltd.

Aurobindo Pharma Limited

Pfizer Inc.

Bayer AG

Viatris Inc.

Merck & Co., Inc.

GSK Plc

Get your Customized Report here: https://www.growthplusreports.com/inquiry/customization/kyphoscoliosis-therapeutics-market/8751

Kyphoscoliosis Therapeutics Market TOC: https://www.growthplusreports.com/report/toc/kyphoscoliosis-therapeutics-market/8751

COVID-19 has had a significant impact on many industries. The pandemic has disrupted global supply chains, leading to shortages of certain goods and materials. It has also resulted in decreased demand for some products and services, as people have been staying home more and spending less money on non-essential items. Many businesses have had to close temporarily or permanently due to lockdowns and social distancing measures. Some industries, such as healthcare, online retail, and delivery services, have seen an increase in demand as a result of the pandemic. Overall, the COVID-19 pandemic has had a significant and far-reaching impact on the global economy.

Market segment by Region/Country including: -

-North America (United States, Canada and Mexico)

-Europe (Germany, UK, France, Italy, Russia and Spain etc.)

-Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

-South America (Brazil, Argentina and Colombia etc.)

-Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

Key takeaways from the Kyphoscoliosis Therapeutics market report:

Detailed considerate of Kyphoscoliosis Therapeutics market-particular drivers, Trends, constraints, Restraints, Opportunities and major micro markets.

Comprehensive valuation of all prospects and threat in the In depth study of industry strategies for growth of the Kyphoscoliosis Therapeutics market-leading players.

Kyphoscoliosis Therapeutics market latest innovations and major procedures.

Favorable dip inside Vigorous high-tech and market latest trends remarkable the Market.

Conclusive study about the growth conspiracy of Kyphoscoliosis Therapeutics market for forthcoming years.

Directly Purchase this premium report now at flat 20% discount: https://www.growthplusreports.com/checkout-8751

Visit our report store at - https://www.growthplusreports.com/report-store

Manan Sethi

Director, Market Insights

Email: sales@growthplusreports.com

256 Chapman Road

STE 105-4, Newark,

New Castle - 19702, USA

Phone no: +1 888 550 5009

Web: https://www.growthplusreports.com/

About us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

[maxsmith059]

Global Periodic Fever Syndrome Market to be Driven by Increasing Investments in the Research and Development Activities in the Forecast Period of 2021-2026 | ExpertMarketResearch.Com

The new report by Expert Market Research titled, ‘Global Periodic Fever Syndrome Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global periodic fever syndrome market, assessing the market based on its segments like treatments, indications, routes of administration, distribution channels, end uses, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2015-2025), along with business strategies and detailed market segmentation, please click on the request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/periodic-fever-syndrome-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The global periodic fever syndrome market would have a positive outlook in the forecast period due to robust investments in the research and development in the developing medicines. The American College of Rheumatology provides education and support for children and families living with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA), which is expected aid the market growth in the coming years.

Industry Definition and Major Segments

A periodic fever syndrome is a group of disorders in which a person experiences recurrent episode of fever over time, usually accompanied by the same symptoms. Each episode of fever usually lasts roughly the same length of time. These disorders are very rare genetic conditions. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is the most common type of periodic fever syndrome. Other common types include familial Mediterranean fever (FMF).

Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/periodic-fever-syndrome-market

The market on the basis of treatment can be divided into:

Oral Anti-Inflammatory Drugs

Non-Steroidal Anti-Inflammatory Drugs

Anti-TNF Therapy

Statins

Others

On the basis of indication, the market is divided into:

Hyperimmunoglobulinemia D Syndrome

Familial Mediterranean Fever

TNF Receptor-Associated Periodic Syndrome

Cryopyrin-Associated Periodic Syndrome

Others

The routes of administration can be divided into:

Oral

Injections

Others

The distribution channels can be categorised as follows:

Hospital Pharmacy

Retail Pharmacy

Online

Others

On the basis of end use, the industry can be categorized into:

Hospitals

Speciality Centres

Others

Read Latest Reports on Periodic Fever Syndrome@ https://www.expertmarketresearch.com/pressrelease/global-periodic-fever-syndrome-market

The regional markets for the product can be divided as follows:

1 North America 1.1 United States of America 1.2 Canada 2 Europe 2.1 Germany 2.2 United Kingdom 2.3 France 2.4 Italy 2.5 Others 3 Asia Pacific 3.1 China 3.2 Japan 3.3 India 3.4 ASEAN 3.5 Others 4 Latin America 4.1 Brazil 4.2 Argentina 4.3 Mexico 4.4 Others 5 Middle East & Africa 5.1 Saudi Arabia 5.2 United Arab Emirates 5.3 Nigeria 5.4 South Africa 5.5 Others

Market Trends

The rising funding from healthcare organisations into the treatment of this syndrome is expected to propel the market growth in the coming years. NHS England has funded a ‘life-changing treatment’ for individuals with periodic fever syndromes. NHS, the public health system of England, is working in collaboration with Novartis to help reduce the frequency of flares in children and adults with the syndrome through the use of the immunomodulatory drug canakinumab (Ilaris). Such developments and programmes are expected to promote the growth of the market in the coming years.

Key Market Players

The major players in the market are Swedish Orphan Biovitrum AB, Novartis AG, and Texas Allergy Group, PLLC, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Related Reports:

Global Medical Wellness Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/348nb30

Global Galvanic Skin Response Sensor Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/2KkNBYk

Global Ascites Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37gfSsc

Global Cleanroom Technology Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37hvawJ

Global Umbilical Cord Blood Banking Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3gOjh4r

Global Pulmonary Artery Catheter Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/2W9uS4C

Global Cranial Electrotherapy Stimulation Devices Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3qUZhly

Global Anoscope Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37l2tPH

Global External Ventricular Drain Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3mbdEOU

Global Nasal Aspirators Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/34aCJDu

Note 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients’ needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

We also provide state-of-the-art procurement intelligence through our platform, https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.

Informes de Expertos (https://informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish-speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.

Determined to bring client satisfaction, we make sure that our tailored approach meets the client’s unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.

Contact Information: Company Name: Expert Market Research Contact Person: Max Smith, Corporate Sales Specialist – U.S.A. Email: sales@expertmarketresearch.com Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website: https://www.expertmarketresearch.com